Inflammation: Opportunities for treatment stratification among individuals diagnosed with mood disorders

Dialogues in Clinical Neuroscience

Volumn 19, Issue 1, 2017, Pages 27-36

  Subramaniapillai, Mehala ^a   Carmona, Nicole E ^a   Rong, Carola ^a   McIntyre, Roger S ^b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anti inflammatory agent; Glutamate; L methylfolate; Patient stratification; Treatment selection

Indexed keywords

ANTIINFLAMMATORY AGENT; BENZOTHIAZOLE DERIVATIVE; FOLIC ACID; FOLIC ACID DERIVATIVE; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; INFLIXIMAB; LAMOTRIGINE; METHYLFOLATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT;

ARTICLE; DRUG EFFECT; GLUTAMATERGIC SYNAPSE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; INNATE IMMUNITY; METABOLIC PARAMETERS; MOOD DISORDER; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; TREATMENT PLANNING; GLUTAMATERGIC SIGNALING; NERVE CELL PLASTICITY; PRIORITY JOURNAL; IMMUNOLOGY; MOOD DISORDERS; PHYSIOLOGY; PSYCHOLOGY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; FOLIC ACID; GLUTAMIC ACID; HUMANS; INFLAMMATION; MOOD DISORDERS; TREATMENT OUTCOME;

EID: 85020387335     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105
2. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA. 2005;293(20):2528-2530
3. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry. 2005;62(10):1097-1106
4. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011;68(3):241
5. Grant BF, Stinson FS, Dawson DA, Chou SP. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders. Arch Gen Psychiatry. 2004;61(8):807-816
6. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-2196
7. McElroy SL, Keck PE. Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J Clin Psychiatry. 2014;75(1):46-61
8. Gans RO. The metabolic syndrome, depression, and cardiovascular disease: interrelated conditions that share pathophysiologic mechanisms. Med Clin North Am. 2006;90(4):573-591
9. Charles EF, Lambert CG, Kerner B. Bipolar disorder and diabetes mellitus: evidence for disease-modifying effects and treatment implications. Int J bipolar Disord. 2016;4(1):13
10. De Hert M, Correll Cu, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52-77
11. Mansur RB, Brietzke E, McIntyre RS. Is there a 'metabolic-mood syndrome'? A review of the relationship between obesity and mood disorders. Neurosci Biobehav Rev. 2015;52:89-104
12. McIntyre RS, Soczynska JK, Konarski JZ, et al. Should depressive syndromes be reclassified as 'metabolic syndrome type II'? Ann Clin Psychiatry. 19(4):257-264
13. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry. 2004;65(5):634-51
14. Mather AA, Cox BJ, Enns MW, Sareen J. Associations of obesity with psychiatric disorders and suicidal behaviors in a nationally representative sample. J Psychosom Res. 2009;66(4):277-285
15. Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67(3):220-229
16. McIntyre RS, Konarski JZ, Wilkins K, Soczynska JK, Kennedy SH. Obesity in bipolar disorder and major depressive disorder: results from a national community health survey on mental health and well-being. Can J Psychiatry. 2006;51(5):274-280
17. Berlim MT, Fleck MP, Turecki G. Current trends in the assessment and somatic treatment of resistant/refractory major depression: an overview. Ann Med. 2008;40(2):149-159
18. Little A. Treatment-resistant depression. Am Fam Physician. 2009;80(2):167-172
19. Poo SX, Agius M. Atypical anti-psychotics in adult bipolar disorder: current evidence and updates in the NICE guidelines. Psychiatr Danub. 2014;26(suppl 1):322-329
20. Edwards SJ, Smith CJ. Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: a mixed treatment comparison of randomized controlled trials. Clin Ther. 2009;31(pt 1):1345-1359
21. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapyassociated weight gain. J Clin Psychiatry. 2003;64(12):1426-1435
22. Torrent C, Amann B, Sánchez-Moreno J, et al. Weight gain in bipolar disorder: pharmacological treatment as a contributing factor. Acta Psychiatr Scand. 2008;118(1):4-18
23. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry. 2001;46(3):273-281
24. Currier MB, Nemeroff CB. Inflammation and mood disorders: proinflammatory cytokines and the pathogenesis of depression. Inflammation. 2010;9(3):212-220
25. McNamara RK, Lotrich FE. Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target? Exp Rev Neurother. 2012;12(9):1143-1161
26. Abbas Abul K, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 8th ed. Philadelphia, PA: Elsevier Health Sciences; 2014
27. Miller DB, O'Callaghan JP. Depression, cytokines, and glial function. Metabolism. 2005;54(5 suppl):33-38
28. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002;64(4):604-611
29. Motivala SJ, Sarfatti A, Olmos L, Irwin MR. Inflammatory markers and sleep disturbance in major depression. Psychosom Med. 2005;67(2):187-194
30. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104(4):788-793
31. Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446-457
32. Munkholm K, Braüner JV, Kessing LV, Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J Psychiatr Res. 2013;47(9):1119-1133
33. Mössner R, Mikova O, Koutsilieri E, et al. Consensus paper of the WFSBP Task Force on Biological Markers: biological markers in depression. World J Biol Psychiatry. 2007;8(3):141-174
34. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71(2):171-186
35. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363-369
36. Guzik TJ, Mangalat D, Korbut R. Adipocytokines-novel link between inflammation and vascular function? J Physiol Pharmacol. 2006;57(4):505-528
37. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 2001;47(3):444-450
38. Brydon L, Harrison NA, Walker C, et al. Peripheral inflammation, stress and sickness responses in healthy men. J Psychosom Res. 2010;68(6):611-612
39. Walker JR, Graff LA, Dutz JP, Bernstein CN. Psychiatric disorders in patients with immune-mediated inflammatory diseases: prevalence, association with disease activity, and overall patient well-being. J Rheumatol Suppl. 2011;88:31-35
40. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS. Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2014;53:23-34
41. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65(9):732-741
42. Kim YK, Na KS, Myint AM, Leonard BE. The role of pro-inflammatory cytokines in neuroinflammation, neurogenesis and the neuroendocrine system in major depression. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;64:277-284
43. Raison C, Miller A. Do cytokines really sing the blues? Cerebrum. 2013;39(14):992-995
44. Postal M, Appenzeller S. The importance of cytokines and autoantibodies in depression. Autoimmun Rev. 2015;14(1):30-35
45. Köhler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71(12):1381-1391
46. Rosenblat JD, Kakar R, Berk M, et al. Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord. 2016;18(2):89-101
47. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31-41
48. Graff LA, Walker JR, Bernstein CN. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis. 2009;15(7):1105-1118
49. Soczynska JK, Kennedy SH, Woldeyohannes HO, et al. Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med. 2011;13(2):93-116
50. Weigle N, Mcbane S. Psoriasis. Am Fam Physician. 2013;87(9):626-633
51. Frol AB, Vasquez A, Getahun Y, Pacheco M, Khan DA, Brown ES. A comparison of clinician-rated neuropsychological and self-rated cognitive assessments in patients with asthma and rheumatologic disorders. Allergy Asthma Proc. 2013;34(2):170-175
52. Haroon E, Miller AH. Inflammation effects on brain glutamate in depression: mechanistic considerations and treatment implications. Curr Top Behav Neurosci. 2016;31:173-198
53. Miller AH, Haroon E, Raison CL, Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety. 2013;30(4):297-306
54. Holtmaat A, Svoboda K. Experience-dependent structural synaptic plasticity in the mammalian brain. Nat Rev Neurosci. 2009;10(9):647-658
55. Whitlock JR, Heynen AJ, Shuler MG, Bear MF. Learning induces longterm potentiation in the hippocampus. Science. 2006;313(5790):1093-1097
56. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology. 2012;62(1):63-77
57. Jun C, Choi Y, Lim SM, et al. Disturbance of the glutamatergic system in mood disorders. Exp Neurobiol. 2014;23(1):28
58. Haroon E, Fleischer CC, Felger JC, et al. Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Mol Psychiatry. 2016;21(10):1351-1357
59. Aan Het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67(2):139-145
60. Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology. 2014;231(18):3663-3676
61. Singh JB, Fedgchin M, Daly EJ, et al. A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry. 2016;173(8):816-826
62. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry. 2015;172(10):950-966
63. Lee SY, Chen SL, Chang YH, et al. Genotype variant associated with add-on memantine in bipolar II disorder. Int J Neuropsychopharmacol. 2014;17(2):189-197
64. Anand A, Gunn AD, Barkay G, et al. Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial. Bipolar Disord. 2012;14(1):64-70
65. Solmi M, Veronese N, Zaninotto L, et al. Lamotrigine compared to placebo and other agents with antidepressant activity in patients with unipolar and bipolar depression: a comprehensive meta-analysis of efficacy and safety outcomes in short-term trials. CNS Spectr. 2016;21(5):403-418
66. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008;28(6):631-637
67. Sanacora G, Smith M, Pathak S, et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. Mol Psychiatry. 2014;19(9):978-985
68. Nagele P, Duma A, Kopec M, et al. Nitrous oxide for treatmentresistant major depression: a proof-of-concept trial. Biol Psychiatry. 2015;78(1):10-18
69. Rogóz Z, Skuza G, Daniel WA, Wójcikowski J, Dudek D, Wróbel A. Amantadine as an additive treatment in patients suffering from drugresistant unipolar depression. Pharmacol Reports. 2007;59(6):778-784
70. Heresco-Levy U, Gelfin G, Bloch B, et al. A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol. 2013;16(3):501-506
71. Preskorn S, Macaluso M, Mehra DO, et al. Randomized proof of concept trial of GLYX-13, an N-methyl-d-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 2015;21(2):140-149
72. Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry. 2007;61(6):822-825
73. Zarate CA, Payne JL, Quiroz J, et al. An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004;161(1):171-174
74. Brennan BP, Hudson JI, Jensen JE, et al. Rapid enhancement of glutamatergic neurotransmission in bipolar depression following treatment with riluzole. Neuropsychopharmacology. 2010;35(3):834-846
75. Blank T, Prinz M. Microglia as modulators of cognition and neuropsychiatric disorders. Glia. 2013;61(1):62-70
76. Pascual O, Ben Achour S, Rostaing P, Triller A, Bessis A. Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proc Natl Acad Sci U S A. 2012;109(4):E197-E205
77. Pittenger C, Coric V, Banasr M, Bloch M, Krystal JH, Sanacora G. Riluzole in the treatment of mood and anxiety disorders. CNS Drugs. 2008;22(9):761-786
78. Kelly DL, McMahon RP, Wehring HJ, et al. Cigarette smoking and mortality risk in people with schizophrenia. Schizophr Bull. 2011;37(4):832-838
79. Stahl SM. l-Methylfolate: a vitamin for your monoamines. J Clin Psychiatry. 2008;69(9):1352-1353
80. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol. 2007;165(1):1-13
81. Peerbooms OL, van Os J, Drukker M, et al. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? Brain Behav Immun. 2011;25(8):1530-1543
82. López-León S, Janssens AC, González-Zuloeta Ladd AM, et al. Metaanalyses of genetic studies on major depressive disorder. Mol Psychiatry. 2008;13(8):772-785
83. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology. 2012;37(1):137-162
84. Papakostas GI, Shelton RC, Zajecka JM, et al. Effect of adjunctive lmethylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014;75(8):855-863
85. Shelton RC, Pencina MJ, Barrentine LW, et al. Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive l-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs. J Clin Psychiatry. 2015;76(12):1635-1641
86. Bowie CR, Gupta M, Holshausen K. Cognitive remediation therapy for mood disorders: rationale, early evidence, and future directions. Can J Psychiatry. 2013;58(6):319-325
87. McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30(6):515-527
88. Lackner N, Bengesser SA, Birner A, et al. Abdominal obesity is associated with impaired cognitive function in euthymic bipolar individuals. World J Biol Psychiatry. 2016;17(7):535-546
89. Bauer IE, Pascoe MC, Wollenhaupt-Aguiar B, Kapczinski F, Soares JC. Inflammatory mediators of cognitive impairment in bipolar disorder. J Psychiatr Res. 2014;56(1):18-27
90. Rosenblat JD, Brietzke E, Mansur RB, Maruschak NA, Lee Y, McIntyre RS. Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: evidence, pathophysiology and treatment implications. J Affect Disord. 2015;188:149-159
91. Galland L. Diet and inflammation. Nutr Clin Pract. 2010;25(6):634-640
92. Ford ES. Does exercise reduce inflammation? Physical activity and Creactive protein among U.S. adults. Epidemiology. 2002;13(5):561-568
93. Stubbs B, Gardner-Sood P, Smith S, et al. Sedentary behaviour is associated with elevated C-reactive protein levels in people with psychosis. Schizophr Res. 2015;168(1-2):461-464